Overview
GCTK market data
Price History
GCTK price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$1.71 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.63 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -3,871.6% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $0.25 – $14.14 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $2.9M · P/B 1.25 · P/S 38.27.
Company News
8-K filing — Glucotrack, Inc. (GCTK)SEC EDGAR · Aug 5, 2026, 9:20 PM
Glucotrack Announces $5.5M Offering Priced At $0.75 Per Unit At Premium To Market, Including $3.5M Convertible Debt From Institutional InvestorsBenzinga · Aug 5, 2026, 12:35 PM
Why Amazon Shares Are Trading Higher By 12%; Here Are 20 Stocks Moving PremarketBenzinga · Jul 31, 2026, 8:49 AM
GlucoTrack Shares Halted On Circuit Breaker To The Upside, Stock Now Up 185.96%Benzinga · Jul 30, 2026, 7:19 PM
GlucoTrack shares are trading higher after the company announced that its subsidiary, Lokahi Therapeutics, is advancing a simplified single-injection strategy for its LT-100 program.Benzinga · Jul 30, 2026, 2:23 PM
Why Microsoft Shares Are Trading Higher By 8%; Here Are 20 Stocks Moving PremarketBenzinga · Jul 30, 2026, 8:29 AM
GlucoTrack (GCTK) Stock Surges Over 70% After Hours: Why is it Moving?Benzinga · Jul 30, 2026, 4:36 AM
GlucoTrack's Subsidiary, Lōkahi Therapeutics, Advances LT-100 Development Strategy Toward Single-Injection Administration; FDA Type C Meeting and Nonclinical Study Advance Strategy To Transition LT-100 From 15 Injections To OneBenzinga · Jul 29, 2026, 9:33 PM
8-K/A filing — Glucotrack, Inc. (GCTK)SEC EDGAR · Jul 29, 2026, 9:15 PM
Glucotrack Has Been Granted U.S. Patent Number 12,129,085 Titled "Methods and systems for continuously monitoring the glucose level of a patient".Benzinga · Jul 28, 2026, 8:04 PM